NEDD9 is an established marker of invasive and metastatic cancers. NEDD9 downregulation has been shown to dramatically reduce cell invasion and metastasis in multiple tumors. The mechanisms by which NEDD9 regulates invasion are largely unknown. In the current study, we have found that NEDD9 is required for matrix metalloproteinase 14 (MMP14) enzymatic recovery/recycling through the late endosomes to enable disengagement of tissue inhibitor of matrix metalloproteinase 2 (TIMP2) and tumor invasion. Depletion of NEDD9 decreases targeting of the MMP14/TIMP2 complex to late endosomes and increases trafficking of MMP14 from early/sorting endosomes back to the surface in a small GTPase ADP ribosylation factor-6 (Arf6)-dependent manner. NEDD9 directly binds to Arf6-GTPase-activating protein, ARAP3 and Arf6-effector GGA3, thereby facilitating the Arf6 inactivation required for MMP14/TIMP2 targeting to late endosomes. Re-expression of NEDD9 or a decrease in Arf6 activity is sufficient to restore MMP14 activity and the invasive properties of tumor cells. Importantly, NEDD9 inhibition by Vivo-Morpholinos, an antisense therapy, decreases primary tumor growth and metastasis in xenograft models of breast cancer. Collectively, our findings uncover a novel mechanism to control tumor-cell dissemination through NEDD9/Arf6-dependent regulation of MMP14/TIMP2 trafficking, and validate NEDD9 as a clinically relevant therapeutic target to treat metastatic cancer.
INTRODUCTION
NEDD9 is a pro-metastatic gene known to be upregulated in different metastatic cancers. [1] [2] [3] It is a cytoplasmic docking protein required for mesenchymal migration and invasion driven by extracellular matrix proteolysis. [3] [4] [5] Genetic ablation of NEDD9 expression in an MMTV-HER2-driven transgenic model of mammary tumorigenesis led to a 90% decrease in the incidence of cancer. 6 As we and others have previously reported, NEDD9 is upregulated during progression to invasive carcinoma, [7] [8] [9] whereas depletion of NEDD9 reduces the number of circulating tumor cells by 80%. 10 NEDD9 is targeted to invasive protrusions and co-localizes with MMP14. We also have shown that NEDD9 does not affect the expression or secretion of MMPs, but markedly decreases their activity. 10 The clinically relevant strategies to decrease NEDD9 expression in established tumors in vivo to abrogate cancer progression were not yet tested, although the potential implications would be highly beneficial.
Activation of soluble MMPs is triggered by membrane-bound MMPs such as MMP14. Activity of MMP14 on the cell surface is regulated by multiple mechanisms, including binding of tissuespecific inhibitor of MMP (TIMP2) and endocytosis. It was shown that endocytosis of MMP14 is stimulated upon binding of TIMP2 11 and almost 80% of MMP14 is recycled back to the cell surface, 12 however, the fate of TIMP2 post internalization is controversial. 11, 13 Upon internalization, MMP14 is localized first to early endosomes and later gets recycled through either early endosomes and the trans-Golgi network 14 or through late endosomes. 15, 16 It is currently unknown whether TIMP2 follows the similar pattern of recycling and degradation. We have previously reported that depletion of NEDD9 leads to a decrease in MMP14 activity and an accumulation of the MMP14/TIMP2 complex on the cell surface. The molecular mechanisms and clinical significance of this phenomenon are unknown.
One of the central signaling hubs regulating endocytic recycling is associated with small GTPase ADP ribosylation factor-6 (Arf6). Arf6 activity is critical for recycling from early/sorting Rab4/5-positive endosomes. 17 Activity of Arf6 is tightly regulated by a number of guanine exchange factors (GEFs) and GTPase-activating proteins (GAPs) to support continuous cycling of Arf6 between GDP-and GTP-bound forms. [18] [19] [20] In this study, we identify NEDD9 as a scaffolding component of the ARAP3-Arf6-GGA3 complex, which is required to decrease the levels of active Arf6 and allow for trafficking of MMP14/TIMP2 complex to late endosomes. This knowledge is crucial for understanding the mechanisms of recovery of MMP14 enzymatic activity and for the development of new strategies for MMPs inhibition and eradication of metastases. This study outlines mechanisms for NEDD9-driven invasion, as well as provides new avenues for the development of alternative strategies to ablate tumor progression based on the manipulation of NEDD9 and ARAP3. 1 
RESULTS

NEDD9 depletion leads to redistribution of MMP14 to the cell surface
The depletion of NEDD9 in invasive mesenchymal breast tumor cell lines (Supplementary Figure S1a) or the genetic ablation of NEDD9 in mouse embryonic fibroblasts from NEDD9 knockout mice leads to a drastic decrease in the activity of soluble and transmembrane MMPs, particularly MMP14. 8, 10 The total amount of MMP14 in the analyzed cells did not change (Figures 1a and b) , but the activity, measured by the degradation of MMP14-specific fluorogenic substrate 21 was drastically decreased (Figures 1c and  d) . Note that the antibodies used for detection of MMP14 are specific and capable of recognizing both pro-and active forms of the enzyme (Supplementary Figures S1b and c) , thus the initial activation of the pro-enzyme by furin was not affected by NEDD9 depletion. Nevertheless, based on a surface biotinylation study, the plasma membrane (PM) levels of MMP14 had increased twofold in the shNEDD9 cells (Figures 1e and f MMP14 on the cell surface is often due to the deficiency in internalization, which is necessary for proper enzyme function. 22, 23 Depletion of NEDD9 does not affect the internalization of MMP14 To determine the impact of NEDD9 expression on MMP14 internalization, we performed time course studies on the uptake of biotinylated surface molecules. Initially, the total amount of biotinylated MMP14 on the cell surface was increased in the shNEDD9 cells (Figure 2a , no strip). Internalization was initiated by shifting the temperature to 37°C, causing the fraction of biotinylated MMP14 to be transported inside the cells (IC-MMP14). We found that the shNEDD9 cells contain twofold less IC-MMP14 than the shControl when normalized to the original amount of biotinylated PM-MMP14 (no strip) (Figures 2a and b) . The amount of IC-MMP14 is the sum of internalization proficiency, intracellular degradation rates and recycling capabilities of the cells. As proteasome and lysosome inhibitors were used during the studies, the decrease in biotinylated IC-MMP14 could not be attributed to the increased degradation of the protein post internalization. However, the decrease could potentially be due to the decreased internalization of MMP14, the PM in general or the increased recycling of the internalized surface molecules. Next, we determined the rates of bulk PM internalization using a CellMask-PM stain and live cell imaging. We found that the decay in fluorescence intensity of CellMask at the PM and perimembrane (2-4 μm beneath the PM) area in shNEDD9 cells was similar to that of the control ( Supplementary Figures S1d and e ; Supplementary Movies S1-S3), suggesting that NEDD9 does not affect bulk PM internalization.
To visualize the trafficking of MMP14, we exogenously expressed previously characterized photoactivatable fluorescent MMP14 (PAmCherry-MMP14 24 ). We imaged the early stages of internalization and translocation of PM-anchored and perimembrane pools of MMP14 after photoactivation in the defined areas (Figure 2c , Supplementary Movies S4-S6). The fluorescence intensity of PA mCherry-MMP14 in the entire cell and perinuclear (near the nucleus) area was measured. The increase in the fluorescence intensity of PAmCherry-MMP14 in the perinuclear area ( Figure 2d ) and the decrease in the original photoactivated area (Figure 2e ) was nearly identical in both the shControl and shNEDD9 cells, suggesting a similar uptake of the MMP14-positive membrane/vesicles. We conclude that NEDD9 deficiency does not alter the internalization of MMP14.
NEDD9 deficiency leads to an increase in the recycling of MMP14 To assess the recycling of MMP14, we used fluorescently labeled anti-MMP14 antibodies in an antibody feeding assay.
14 The siControl and siNEDD9 cells were pretreated with antibodies for 1 h to allow for MMP14 labeling and internalization of the Ab/ MMP14 complex, followed by acidic wash 25 and an additional hour for recycling. Cells were then stained with different anti-MMP14 antibodies to differentiate between the recycled Ab/MMP14 complex and the newly synthesized MMP14. Interestingly, the amount of recycled MMP14, as indicated by co-staining with both the anti-MMP14 antibodies, was increased up to 40% in the shNEDD9 cells (Figures 3a-c) .
Similarly, fluorescence recovery after photobleaching analysis of cells expressing mCherry-MMP14 revealed that siNEDD9 cells recover fluorescent PM-MMP14 to a higher extent with a 1.3-1.7-fold increase in the mobile fraction and a comparable increase in t 1/2 (Figures 3d and e; Supplementary Movies S7-S9). Hence, the decrease in NEDD9 expression leads to an increase in recycling of internalized MMP14.
NEDD9 is involved in the regulation of MMP14 trafficking to late endosomes To understand the route of MMP14 recycling, we assessed the distribution of MMP14 to early and late endosomes. The corresponding compartments were identified by immunofluorescent staining with anti-Rab5 and -Rab7 antibodies. In the shControl cells, about 60% of MMP14 containing vesicles colocalized with Rab5 and about 80% with Rab7. Surprisingly, NEDD9 depletion resulted in a twofold decrease of MMP14 in the Rab7 vesicles and an increase of MMP14 residing in the Rab5 vesicles (Figures 3f and g; Supplementary Figures S1f and g) .
A decrease in MMP14 in late endosomes could arise from an increased degradation of MMP14 or a deficiency of MMP14 sorting/trafficking to late endosomes/lysosomes. To assess the rates of protein degradation, the cells were treated with cycloheximide, an inhibitor of de novo protein synthesis, and the protein levels of MMP14 were measured during a time course study. Surprisingly, the amount of MMP14 protein in shNEDD9 cells was 20% higher than in the control (Supplementary Figures S2a and b) , suggesting that a decrease in NEDD9 leads to a decrease in the degradation of MMP14. Thus, NEDD9 is most likely to be involved in MMP14 sorting/trafficking to late endosomes.
Note that NEDD9 depletion did not affect the tested membrane compartments (Rab7-late endosomes, Rab11-recycling endosomes and Lamp1 lysosomes) as determined by the immunofluorescent staining (Supplementary Figures S2c and d) . The trafficking of other proteins to late endosomes/lysosomes such as EGF (Supplementary Figure S2e) was also not affected. There were no changes in the acidification of the endosomes upon NEDD9 depletion (Supplementary Figures S2f and g ), supporting the notion of a specific action by NEDD9 on MMP14 trafficking.
NEDD9 deficiency leads to the enlargement of early/recycling/ sorting (ERS) compartment Interestingly, NEDD9 deficiency leads to a twofold increase in the volume of the ERS based on a 3D reconstruction of the confocal images (Figures 4a and b ). It is difficult to assess whether the increase was driven by a fewer larger vesicles or by an increase in the total number of Rab4/Rab5-positive vesicles due to the tubular shape of the ERS and the many merging points between the differently shaped vesicles. A western blot analysis of the wholecell lysates revealed no change in the Rab-GTPases expression in the shNEDD9 cells (Supplementary Figures S3a and d) . Nevertheless, reexpression of wild-type NEDD9 was sufficient to rescue the phenotype and reduce the volume of the ERS to the control level (Figures 4c and e) .
Importantly, in the absence of NEDD9, MMP14 gets recycled from the ERS back to the PM (Figures 2 and 3 ). This could potentially be associated with the dysregulation of Arf6-GTPase, 17, 26, 27 which was previously shown to be involved in the recycling of multiple receptors including c-Met.
28
NEDD9 is required to control the levels of active Arf6-GTPase NEDD9 is a scaffolding protein, and through binding to GEFs, like DOCK180 and AND-34, it controls the activation of Rap1 29 and Rac1. 30 Following this trend, we tested the activity of Arf6-GTPase upon NEDD9 manipulation. Surprisingly, overexpression of NEDD9 led to the decrease in Arf6 activity (Supplementary Figure S4a) , whereas the knockdown of NEDD9 resulted in~twofold increase in Arf6 (Figures 5a and b) activity. We did not detect any changes in Arf1 activity upon NEDD9 depletion (Supplementary Figures  S4b and c) , suggesting a specific action by NEDD9 on Arf6. The activation of Arf6 was also indirectly confirmed by an increase in the activity/phosphorylation of the downstream Arf6 target PIP5-α kinase (Supplementary Figure S4d) , and by an increase in membrane invaginations, as previously reported in cells with upregulation of endogenous Arf6 (Supplementary Figure S4e) . 31 We also noticed a moderate decrease in the total amount of the Arf6 protein in cells with constitutive knockdown of NEDD9 (Figures 5a and b) . Interestingly, upon transient siRNA depletion, no changes in the total Arf6 level were observed (Supplementary Figure S4f) , suggesting the existence of a compensatory mechanism for the excessive amount of active Arf6 or reflecting the destabilization of Arf6 in the absence of NEDD9. Re-expression of exogenous NEDD9 in shNEDD9 cells decreased the amount of active Arf6 (Figures 5c and d) . Collectively, our findings suggest that NEDD9 is required to keep activity of Arf6-GTPase balanced, thus providing fine-tuning of GTP/GDP-bound Arf6 cycling and allowing for cargo sorting either for recycling or degradation.
NEDD9 binds to Arf6-GAP, ARAP3 and the effector GGA3 To delineate molecular mechanisms of the NEDD9-driven decrease in Arf6 activity, we screened multiple Arf6-GAPs ( Figure  6a and Supplementary Figure S5a) . We found that NEDD9 specifically binds to ARAP3 (Figure 6a ). The minimum binding fragment resides in the C-terminal domain of NEDD9 (626-834 aa) (Figures 6b and c) . Interestingly, the Arf6-GTP downstream effector, adapter protein GGA3, was also present in the complex with NEDD9 (Figure 6d ), suggesting that the NEDD9/ARAP3 complex is targeted to the active Arf6/GGA3 complex to promote GTP hydrolysis. We also found MMP14 in the complex with GGA3 (Figure 6e ), indicating the involvement of Arf6-GGA3 in MMP14 trafficking.
To define subcellular localization of these proteins, we expressed fluorescently labeled NEDD9 and ARAP3 in tumor cells. Most of the NEDD9 and ARAP3 proteins co-localized at the Arf6-positive vesicles (Figure 6f ), suggesting that the (f and g) Quantification of co-localization of Rab5 (f) and MMP14 or Rab7 (g) and MMP14-positive vesicles as percentage of total MMP14 vesicles; graphs are mean percentage values ± s.e.m.; three independent experiments, 10 cells per treatment; one-way analysis of variance with Dunnett's post hoc analysis Rab5: *P = 0.0154 and P = 0.0087 for Con/N1 or N2; Rab7: *P o0.0001 for Con/N1 or N2; ns, nonsignificant.
membrane-associated Arf6-GTP/GGA3 complex recruits NEDD9 and ARAP3, thereby promoting Arf6 inactivation and complex dissociation.
Decrease in Arf6 activity is sufficient to restore PM-MMP14 levels and its activity To determine the impact of Arf6 activity on MMP14 trafficking, we assessed the level of PM-MMP14 upon partial inhibition of Arf6 by an antagonist of the cytohesin family GEFs, SecinH3, which was previously characterized for Arf6. 32 Treatment of the shNEDD9 cells with SecinH3 or reexpression of wtNEDD9 10 rescued the phenotype leading to a decrease in the amount of PM-MMP14 (Figure 6g) . Moreover, application of SecinH3 restored the degradation capacity and the invasion deficiency (Figures 6h and i) of shNEDD9 tumor cells, indirectly indicating an increase in the activity of MMP14 and soluble MMPs. A publicly available TCGA data set analysis of ARAP3 and NEDD9 mRNA expression revealed a significant correlation in expression of these proteins in breast cancer biopsies, but not in normal tissue (Figures 6j and k) , implying that cooperation between ARAP3 and NEDD9 could be critical for tumor progression. Spearman correlation analysis of NEDD9 and ARAP3 mRNA expression in normal (j) breast tissue or breast cancer biopsies (k) based on TCGA database; n = 105 (for normal breast), n = 791 (for cancer breast), r = −0.1161, P = ns for normal, r = 0.3035, P o0.0001 for tumor; ns, nonsignificant.
NEDD9 promotes MMP14 activity through recycling YV Loskutov et al as a potential mechanism for MMP14 inactivation upon depletion of NEDD9. 10 To test if PM-MMP14 forms a complex with TIMP2 and visualize it, we expressed mCherry-MMP14 and Flag-tagged TIMP2 in shControl and shNEDD9 cells. Increased amounts of the TIMP2/ MMP14 complex were co-immunoprecipitated from shNEDD9 cells (Figures 7a and b) , confirming our previous findings and suggesting a potential decrease in TIMP2/MMP14 dissociation under NEDD9-deficient conditions. Note that no changes in the expression or secretion of TIMP2 were detected upon the manipulation of NEDD9. 10 To identify the cause of the increase in the TIMP2/MMP14 complex, we determined the fate of the internalized TIMP2. The cells expressing mCherry-MMP14 and TIMP2-Flag were fed with anti-Flag antibodies to visualize the TIMP2 internalization. The shNEDD9 cells showed a twofold decrease in targeting TIMP2 to late endosomes based on colocalization with Rab7-positive vesicles (Figures 7c and d) . We also noted a robust increase in surface TIMP2 upon NEDD9 depletion. Overall, these data suggest that the TIMP2/MMP14 complexes are dissociating/degrading less efficiently in NEDD9-deficient cells owing to the impaired targeting to the late endosomes, where TIMP2 gets released from MMP14 in a pH-dependent manner. 13, 34 However, further studies are required to delineate the fate of TIMP2 targeted to late endosomes and the potential for TIMP2 recycling.
11,13
Collectively, our findings suggest a model (Figure 7e ) in which NEDD9 scaffolds the interaction between ARAP3 and the Arf6- 
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Downregulation of NEDD9 via siNEDD9-Vivo-Morpholino treatment decreases tumor progression in a xenograft model of breast cancer NEDD9 overexpression is a feature of invasive human cancers with increased metalloproteinase activity. Unfortunately, the anti-MMP cancer therapy did not yield the expected results in the clinic, hence targeting alternative processes that control the activity of MMPs might prove to be a viable anti-metastasis strategy. Therefore, we wanted to determine whether NEDD9 knockdown via treatment with antisense oligonucleotides targeting NEDD9 that have been modified for in vivo applications (moNEDD9-VivoMorpholinos) (Figures 8a and b) affects tumor growth and metastasis in a mouse xenograft model using MDA-MB-231LN cells. We found a significant decrease in the size of primary tumors and metastases in lungs of mice treated with moNEDD9 compared with moControl after only 1 week of treatment (Figures 8c and e) . The primary tumors exhibited a striking decrease in viability and proliferation based on the mitotic index and the percentage of necrotic tissue evaluated by pathology. These results indicate that NEDD9 depletion in established highly metastatic tumors decreases growth and further dissemination of breast cancer cells. Importantly, these data provide the first clinical evidence of the potent anti-tumorigenic activity of NEDD9 targeted siRNAs in vivo and evaluates NEDD9 as a novel therapeutic target.
DISCUSSION
Recent studies have established NEDD9 as an essential factor for invasive 1,2 and metastatic behavior in tumors. [3] [4] [5] The results of this study establish a novel role for NEDD9 as a key regulator of Arf6-dependent trafficking of MMP14, highlighting the basic mechanism utilized by NEDD9 to support cancer cell invasion and metastasis. The cancer cell lines 35 used in this study utilize the mesenchymal type of invasion; 36 however, we are not excluding the possibility of similar effects of NEDD9 on collective cell migration where the leading cells (or recruited fibroblasts) often utilize MMP-dependent invasion. 37 This mechanism might be involved in the regulation of other known NEDD9 functions including focal adhesion disassembly 38 and integrin signaling. 39 Expression and activity of MMP14 is critical for normal morphogenesis and tumor progression. [40] [41] [42] Although nearly 80% of the internalized MMP14 is recycled, little is known about the regulation of this process. 12, 22 Several studies reported recycling of MMP14 from early and late endosomes, 14, 15, 24 but the key molecules defining the route of recycling for MMP14 are still unknown. Even less is known about the fate of TIMP2, an MMP14 ligand involved in MMP2 activation.
11-13 As we previously indicated, NEDD9 depletion leads to a decrease in activation of MMP2 and MMP9, thus affecting the ability of cancer cells to invade. 43 The TIMP2 is internalized with MMP14, 12 and is either degraded 11 or recycled. 13 Interestingly, the documented pH required for TIMP2 dissociation 13 is reached only in the late endosomes. 34 Thus, recycling of the MMP14/TIMP2 complex through late endosomes might be required for reactivation of the TIMP2-bound enzyme.
In our study, we stumbled upon a paradoxical observation where the depletion of NEDD9 resulted in a decrease in MMP14 activity, concomitant with an increase in the amount of PM-MMP14. Our data suggests that the main form of MMP14 present in tested cells is active furin-processed MMP14 (Supplementary Figure S1c) . NEDD9 deficiency does not interfere with furindependent activation of MMP14 based on no changes in MMP14 size or internalization, 44 but rather leads to a decreased targeting of the TIMP2/MMP14 complex to late endosomes and an increase in recycling from the ERS compartment. This indicates the switch from recycling through late endosomes to the ERS-recycling pathway.
NEDD9 is known to activate small GTPase Rac1, 30 cdc42 45 and Rap1, driving mesenchymal migration and T-cell activation. 29 Therefore, we decided to check whether NEDD9 regulates MMP14 recycling through small GTPases. Surprisingly, NEDD9 was involved in inactivation of Arf6-GTPase. Arf6 regulates key aspects of endocytic recycling. 46, 47 The activity of Arf6 is closely controlled by a number of GEFs, including GEP100 48 and ARNO, 49 and also GAPs such as ACAP1, 50 ASAP1 and ARAP3. We found that NEDD9 interacts with ARAP3 and the Arf6 downstream effector GGA3. 28 The NEDD9 depletion phenotype resembles the previously published aluminum fluoride induced increase in the activity of endogenous Arf6 27 rather than overexpression of a constitutively active Arf6, Arf6Q67L. 31, 51, 52 A twofold increase in the amount of Arf6-GTP, in the case of NEDD9 depletion, did not result in an accumulation of large actin-positive vesicles, but instead both increased the volume of vesicles in the early endocytic compartment and also Arf6-dependent recycling to the PM, similar to a phenotype previously reported. 53 Moreover, in the case of NEDD9 depletion, there is no overexpression of Arf6 protein, but rather a decrease, indicating the existence of a potential feedback loop to reduce the activity of Arf6 via a decrease in protein stability or expression.
The increase in the activity of endogenous Arf6 upon NEDD9 depletion was further confirmed by an analysis of its downstream target-phosphatidylinositol-4-phosphate-5-kinase (PIP5K). 26 Activation of PIP5K could explain the increased number of membrane invaginations and ruffling in NEDD9-deficient cells, which was also previously reported in cells with increased Arf6 activity.
54 NEDD9 deficiency does not abolish proper sorting of cargoes or maturation of endosomes, as shown by live cell imaging using RFP-Rab5/Rab7 and Alexa647-EGF. However, the distribution of MMP14 to different endosomal compartments is affected and its recycling is re-routed. The same redistribution was observed for TIMP2. Previously, a similar phenomenon was documented for GGA3, which is required for targeting the c-Met receptor for recycling instead of degradation. 28 In our current work, we found MMP14 in a complex with GGA3, suggesting the possibility of similar regulation of MMP14. We proposed a model where NEDD9 controls the switch of MMP14 recycling through the ERS versus late endosomes (Figure 7e ). Previously MMP14 was reported to be recycled through a Rab8-dependent mechanism. 55 We did not observe any changes in the level of Rab8 (Supplementary Figure S3c and d) , however we are not excluding the possibility of crosstalk between Arf6 and Rab8 in regulation of MMP14 trafficking, as the Arf6-and Rab8-positive compartments are largely overlapping. 56 Ablation of the MMP14 gene causes severe developmental defects, 57 suggesting that the activity of MMP14 cannot be substituted by any other MMP. Attempts in developing selective MMP14 small-molecule inhibitors have been so far unsuccessful. 58 Hence, binding partners that modulate MMP14 activity may represent an attractive avenue for MMP14 inhibition. Alteration of NEDD9 expression in tumor cells thus provides a novel regulatory mechanism for controlling invasive properties via MMP14. 59 The decrease in tumor progression upon inhibition of NEDD9 by antisense therapy in human breast cancer xenografts supports this notion and might allow for a targeted decrease in MMP activity in the tumor, thus providing a novel therapeutic approach to block the spreading of cancer.
MATERIALS AND METHODS
Plasmids and cell culture
Cell lines, HEK293T (ATCC, Manassas, VA, USA), Hs578T (ATCC) and MDA-MB-231LN (Caliper LifeSciences, Hopkinton, MA, USA), were grown according to the manufacturer's recommendations. shRNAs and siRNAs against NEDD9, nontargeting control (ThermoFisher Scientific, Waltham, MA, USA), and NEDD9-cDNA were prepared as previously described. 7 mRFP-Rab5 and -Rab7 were purchased from Addgene (plasmid #14437 and #14436). 60 Plasmids mCherry-MMP14 and PAmCherry-MMP14 were a gift from Dr Chavrier (Institute Curie, France) and Dr Machesky (The Beatson Institute for Cancer Research, Scotland). 24 Human TIMP2-cDNA (ThermoFisher Scientific) was sub-cloned into pcDNA3.1-3x-Flag plasmid (gift from Dr Frisch, West Virginia University, USA). 
Extracellular matrix-coated Boyden chamber invasion assays
Assays were carried out according to the manufacturer's protocol and as previously described. 7 Fluorescent-gelatin degradation assay Assay was performed as previously described. 10, 61 Fluorescence-activated cell sorting Assay was performed as previously described. 10 Protein expression, western blotting and immunoprecipitation For pull-down (PD) assays, the recombinant GST-tagged GGA3-VHS-GAT domain was produced in Bl21(DE3) Escherichia coli as previously described. 62 Western blotting was done as previously described. 62 Primary antibodies against NEDD9 mAb (2G9), 62 PIP5K, phS309-PIP5K, MMP14 (Novus International, St Charles, MO USA), Flag (Sigma-Aldrich, St Louis, MO, USA), Arf6, (Santa-Cruz Biotech, Dallas, TX, USA), GAPDH (Millipore, Billerica, MA, USA), GFP, EEA1 (BD Bioscience, San Jose, CA, USA), GGA3, RFP (ThermoFisher), GFP, LAMP1/2 (Developmental Studies Hybridoma Bank, Iowa City, IA, USA), and Rab4, 5, 7, 8 and 11 (Cell Signaling Technology, Danvers, MA, USA) were used. Bands were digitized and quantified using a digital documentation and image analysis system (Syngene, Frederick, MD, USA).
Immunofluorescence
Cells were processed as previously described. 62 Primary antibodies against Rab4, 5, 7, 9, 11 (Cell Signaling Technology), Lamp1 (NIH Hybridoma Bank), Arf6 (Santa-Cruz Biotech), MMP14 (Novus International), MMP14-488 (R&D Systems, Minneapolis, MN, USA), EEA1 (BD Bioscience) were used. Secondary antibodies included AlexaFluor 405, 488, 555 and 647 (Life Technologies, Carlsbad, CA, USA). Images were captured using a standard setting by a confocal microscope LSM510 (Zeiss, Thornwood, NY, USA). All images represent whole-cell 3D reconstructed projections with 0.25 μm steps.
Cell surface Biotinylation assay
Cells pretreated with 10 μM MG132 and 50 μM Leupeptin (FisherScientific) were labeled at 4°C with Sulfo-NHS-S-S-biotin (ThermoFisher Scientific) in phosphate-buffered saline (PBS), followed by incubation at 37°C for internalization of surface molecules. Residual surface biotinylation was removed by incubation with 200 mM MESNA (Sigma) for 30 min. Cells were homogenized in PTY buffer, 62 and biotinylated molecules were pulled down with streptavidin-conjugated agarose (Millipore) and used for western blotting.
Live cell imaging: endocytosis Cells were plated on delta T4 glass bottom dishes (FisherScientific, Pittsburgh, PA, USA), labeled with EGF-647 or CellMask DeepRed (LifeTechnologies) in the presence of 0.45 M sucrose, and imaged by a LSM510 (Zeiss) or NikonLiveScan SFC microscope equipped with perfect focus x-y stage control and z-axis motor (Nikon Instruments, Melville, NY, USA), Photometrics QuantEM CCD camera (Photometrics, Tucson, AZ, USA), and a 60X PlanFluor, NA1.21 objective. Images were captured every 5 s for 30 min. NIS (Nikon Instruments) and ImageJ (NIH) software (http://rsb.info. nih.gov/ij) were used for data processing and analysis. To compare rates of internalization, small areas corresponding to cell margins were selected and fluorescence intensities throughout the movie were measured.
Flurescence recovery after photobleaching analysis Cells were transfected with mCherry-MMP14 and siRNAs against NEDD9, plated on glass bottom dishes (InVitro Scientific), imaged with LSM510 (Zeiss) microscope both before and after photobleaching of the designated area every 15 s for 5 min. The collected movies were analyzed with ImageJ software (NIH).
Trafficking of PAmCherry-MMP14
Cells were transfected with mCherry-MMP14 and siNEDD9, plated on glass bottom dishes (InVitro Scientific), and imaged 24 h later with a LSM510 (Zeiss) confocal microscope both before and after photoactivation of the designated area every 15 s for 5 min. The collected movies were analyzed with ImageJ software (NIH).
MMP14 recycling assay
Cells were transfected with mCherry-MMP14 and siNEDD9. Mouse monoclonal anti-MMP14 antibodies conjugated with AlexaFluor-488 (R&D Systems) were added to the cells for 1 h at 37°C. Cells were washed with acidic strip solution, 25 and the Ab/MMP14 complex was allowed to recycle for 1 h at 37°C, followed by fixation with 4% PFA/PBS and processed for immunofluorescence (without permeabilization).
MMP14/TIMP2 intracellular distribution
The cells were transfected with mCherry-MMP14 or PAmCherry-MMP14 and TIMP2-Flag. The anti-MMP14-488 or anti-Flag antibodies were added to the cells for 1 h at 37°C, fixed with 4% PFA/PBS and processed for immunofluorescence.
Transmission electron microscopy Cells were fixed with 2.5% glutaraldehyde or 2% paraformaldehyde, post fixed in 1% osmium tetroxide for 1 h, stained with uranyl acetate, and processed for conventional ultrathin sectioning. Sections were post stained with uranyl acetate and lead citrate, and imaged with a Zeiss Libra120 (Zeiss) transmission electron microscope.
Arf6/Arf1 activity assessment
The assay was performed using an active Arf6 PD and Detection Kit (Pierce Biotechnology, Rockford, IL, USA) or Arf1 Activation Assay Kit (Cell Biolabs, San Diego, CA, USA) according to the manufacturer's protocols.
Correlative analysis of NEDD9 and ARAP3 in breast cancer TCGA (NIH) data sets of 791 human breast cancer microarrays and 105 normal tissue microarrays were used for analysis with the GraphPad Prism package (GraphPad Software, La Jolla, CA, USA) with Spearman correlation analysis.
MMP14 activity assay
In all, 4x10 4 cells/well were plated on a 96-well plate. MMP14 fluorogenic substrate (Millipore) was added in L15-medium for 4 h. Fluorescence was measured by plate-reader SynergyH4 (BioTec) at 328/400 nm excitation/ emission.
Animal bioluminescence imaging of mammary fat pad xenografts
Nod/SCID/gamma (NSG)-immunodeficient mice (Jackson Laboratory, Bar Harbor, ME, USA) were housed in the West Virginia University Animal Facility under pathogen-free conditions with an approved Institutional Animal Care and Use Committee protocol. The tumor injection and analysis was performed as previously described. 8, 11 The moNEDD9-or moControlVivoMorpholino (GeneTool, Philomath, OR, USA) treatment was initiated 2 weeks post tumor-cell injection. Animals with tumors of similar volume were injected by immunoprecipitated with 12.5 mg/kg of VivoMorpholinos dissolved in PBS daily for 1 week. The average lung and primary tumor radiance was measured at each time point. The mammary fat pads and lungs were collected at the end of the study, fixed, and pathologically analyzed for the number of mitotic tumor cells, percentage of necrosis and number/size of metastases as described 8 by a pathologist (MBS).
Statistical analysis
Statistical comparisons were made using two-tailed Student's t-test. When more than two groups were analyzed, one-way analysis of variance was used. P ≤ 0.05 was considered to be significant. Experimental values were reported as the means ± s.e.m. All calculations of statistical significance were performed using the GraphPad Prism package (GraphPad Software, Inc.).
